Hydroxychloroquine in rheumatic autoimmune disorders and beyond

Eliise Laura Nirk, Fulvio Reggiori, Mario Mauthe*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

36 Citaten (Scopus)
135 Downloads (Pure)

Samenvatting

Initially used as antimalarial drugs, hydroxychloroquine (HCQ) and, to a lesser extent, chloroquine (CQ) are currently being used to treat several diseases. Due to its cost-effectiveness, safety and efficacy, HCQ is especially used in rheumatic autoimmune disorders (RADs), such as systemic lupus erythematosus, primary Sjögren's syndrome and rheumatoid arthritis. Despite this widespread use in the clinic, HCQ molecular modes of action are still not completely understood. By influencing several cellular pathways through different mechanisms, CQ and HCQ inhibit multiple endolysosomal functions, including autophagy, as well as endosomal Toll-like receptor activation and calcium signalling. These effects alter several aspects of the immune system with the synergistic consequence of reducing pro-inflammatory cytokine production and release, one of the most marked symptoms of RADs. Here, we review the current knowledge on the molecular modes of action of these drugs and the circumstances under which they trigger side effects. This is of particular importance as the therapeutic use of HCQ is expanding beyond the treatment of malaria and RADs.

Originele taal-2English
Artikelnummer12476
Aantal pagina's17
TijdschriftEMBO Molecular Medicine
Volume12
Nummer van het tijdschrift8
DOI's
StatusPublished - 26-jul-2020

Citeer dit